Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KBADU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HLL1-CL2A-SN38
|
|||||
| Synonyms |
HLL1 CL2A SN38
Click to Show/Hide
|
|||||
| Organization |
Immunomedics, Inc.; Gilead Sciences, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Milatuzumab
|
Antibody Info | ||||
| Antigen Name |
HLA class II histocompatibility antigen gamma chain (CD74)
|
Antigen Info | ||||
| Payload Name |
Active metabolite of irinotecan SN38
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Inter-chain cysteine.
|
|||||
| Combination Type |
Govitecan
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.